You are here: Home » Markets » News
Business Standard

Laurus Labs trades higher for fourth straight day; stock hits record high

The stock has outperformed the market in past four months. It has rallied 171 per cent since June on the back of strong quarterly earnings.

Laurus Labs | Buzzing stocks | Markets

SI Reporter  |  Mumbai 

Laurus Labs
For the April-June 2020 quarter (Q1FY21), Laurus Labs posted consolidated revenue of Rs 974 crore, up 77 per cent year-on-year (YoY).

Shares of hit a record high of Rs 1,263, up 4 per cent on the BSE in the intra-day trade on Thursday. The stock of the pharmaceutical company was trading higher for the fourth straight day, gaining 7 per cent during the period. It surpassed its previous high of Rs 1,263 touched on August 24, 2020, in the intra-day trade.

has outperformed the S&P BSE Sensex in the past four months. Since June, it rallied 171 per cent on strong quarterly earnings. In comparison, the benchmark index was up 19 per cent during the same period.

is a leading research-driven pharmaceutical manufacturing company in India. The company has grown to become one of the leading manufacturers of API for anti-retroviral (ARV), oncology, cardiovascular, anti-diabetics, anti-asthma, and gastroenterology.

The board of directors of the company has fixed September 30, 2020, as the record date for the sub-division of equity shares of the company from the existing face value of Rs 10 each to Rs 2 each. The company announced, on April 30, its stock split plan to make the stock more affordable for the small retail investors and increase liquidity.

For the April-June 2020 quarter (Q1FY21), Laurus Labs posted consolidated revenue of Rs 974 crore, up 77 per cent year-on-year (YoY) while earnings before interest, taxes, depreciation, and amortisation (EBITDA) stood at Rs 285 crore, up 288 per cent YoY. EBITDA margin came in at 29 per cent while net profit or profit after tax (PAT) zoomed 1,047 per cent YoY to Rs 172 crore.

Ambit Capital maintains ‘buy’ rating on the stock with the target price of Rs 1,295 per share. The brokerage firm has substantially upgraded FY21/22 EPS to Rs 63/Rs 74 from Rs 38/ Rs 41, owing to incremental projects in CRAMS; EFV API sales uptick and customer wins in non-ARV APIs with 20 per cent capacity expansion underway.

At 11:45 am, Laurus Labs was trading 1.5 per cent higher at Rs 1,230 on the BSE, as compared to a 1.3 per cent rise in the S&P BSE Sensex. A combined 982,000 equity shares had changed hands on the counter on the NSE and BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, September 10 2020. 11:47 IST